文献速递神经肌肉病

比马鲁单抗治疗散发性包涵体肌炎的长期安全性与耐受性

Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis.
PubMed 文献 · Neurology · 2020-07-20

这项多中心开放标签扩展研究纳入10例完成单剂核心研究的散发性包涵体肌炎成人,每4周静脉给予比马鲁单抗10 mg/kg,最长104周。所有受试者均因研究提前终止或不良事件停药,常见不良事件为肌肉痉挛和跌倒(各90%);大腿肌肉体积和瘦体重增加,但6分钟步行距离进行性下降,无临床改善证据。

要点

  • 比马鲁单抗10 mg/kg每4周静脉给药最长2年,在sIBM中安全性和耐受性良好。
  • 所有受试者均停药,3例因不良事件停药且均与治疗无关。
  • 肌肉量增加但6分钟步行距离进行性下降,无功能改善证据。

核心结论

  • 比马鲁单抗长期治疗最长2年在sIBM患者中安全且耐受性良好,但无临床改善证据。

研究设计与样本

  • 多中心开放标签扩展研究,纳入10例完成单剂核心研究的sIBM成人,每4周静脉给予比马鲁单抗10 mg/kg,最长104周。

主要发现

  • 所有受试者(n=10)均停药:7例因研究提前终止,3例因不良事件(心肌梗死、食管癌、痴呆,均与治疗无关)。
  • 最常见不良事件为肌肉痉挛和跌倒(各9/10,90%),其次为腹泻(6/10,60%)、痤疮和皮疹(各5/10,50%)。
  • 第8周和第16周大腿肌肉体积较基线平均增加4.1%(SD 4.3%)和4.5%(SD 6.3%)。
  • 瘦体重较基线增加,第76周维持平均增加6.9%(SD 3.9%)。
  • 6分钟步行距离从基线至第76周进行性下降,握力轻度数值增加,股四头肌力量无显著变化。

关键数值与推荐

  • 比马鲁单抗10 mg/kg静脉给药,每4周一次,最长104周。
  • 安全性主要终点通过记录不良事件评估。

临床怎么用

  • 长期比马鲁单抗治疗在sIBM中安全性可接受,但未显示功能改善,不支持以改善功能为目的的临床使用。

局限性

  • 开放标签、单臂、样本量小(n=10),所有受试者均停药,研究提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the long-term safety and tolerability and to monitor benefits of extended use of bimagrumab in individuals with sporadic inclusion body myositis (sIBM) who completed a single-dose core study. METHODS: In this multicenter, open-label extension study, 10 adults received bimagrumab 10 mg/kg IV every 4 weeks up to 2 years (104 weeks). Safety (primary endpoint) was assessed by recording adverse events (AEs). Clinical benefits were assessed by changes from baseline in thigh muscle volume (TMV), lean body mass (LBM), 6-minute walk distance (6MWD), handgrip, and quadriceps strength. RESULTS: Participants had a mean age of 70.1 (SD 10.4) years. All participants (n = 10) discontinued the treatment due to early termination of the study (n = 7) or AEs (n = 3; myocardial infarction, esophageal carcinoma, and dementia, none of which were treatment related). The most common AEs were muscle spasms and falls (both 9 of 10, 90%), followed by diarrhea (6 of 10, 60%) and acne and skin eruption (both 5 of 10, 50%). At weeks 8 and 16, mean TMV increased from baseline by 4.1% (SD 4.3%) and 4.5% (SD 6.3%). Mean LBM increased from baseline and was sustained at 6.9% (SD 3.9%) at week 76. Means of 6MWD showed a progressive decline from baseline to week 76, during which there was a modest numerical increase in handgrip strength and no significant changes in quadriceps strength. CONCLUSIONS: Long-term treatment up to 2 years with bimagrumab had a good safety profile and was well tolerated in individuals with sIBM. An increase in muscle mass was noted on a group level; however, there was no evidence of clinical improvement. CLINICALTRIALSGOV IDENTIFIER: NCT02250443. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with sIBM, long-term bimagrumab treatment was safe and well tolerated and did not lead to functional improvement.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Sivakumar K, Cochrane TI, Sloth B, et al. Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis. Neurology. 2020. PMID: 32690797. doi:10.1212/WNL.0000000000010417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。